ADAPTIVE BIOTECHNOLOGIES CORPORATION Payments of Stock Issuance Costs
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Payments of Stock Issuance Costs of $321.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-02-14
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments of stock issuance costs for the quarter ending 2020-12-31 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments of stock issuance costs for the quarter ending 2019-12-31 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments of stock issuance costs for the quarter ending 2019-09-30 was $1.63M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments of stock issuance costs for fiscal 2020 was $321.00K, a 93.56% decline from fiscal 2019.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments of stock issuance costs for fiscal 2019 was $4.99M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $321.00K 10-K · filed 2023-02-14 | ||
| 2020-09-30 | $321.00K 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $1.63M derived: sum of 2 quarters · filed 2022-02-15 | $4.99M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $4.99M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $3.36M 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |